MHRA grants marketing authorisation (MA) to cenobamate (Ontozry) for adjunctive treatment of focal-onset seizures, with or without secondary generalisation

MA covers use of this sodium channel blocker (SCB), with a binding site different from that of classical SCBs, in adults with epilepsy who have not been adequately controlled despite treatment with ≥2 anti-epileptic drugs, and is supported by data from CO17 and CO21 trials.

PharmaTimes